Mivacurium is a benzylisoquinolone, choline-like, non-depolarizing muscle relaxant. Its onset of action is similar to that of atracurium but its duration of action is shorter (approximately 10-15 minutes). Mivacurium is metabolized by plasma cholinesterases at approximately 70% of the rate of metabolism of suxamethonium 1 . Deficiency or abnormality of plasma cholinesterase may cause the duration of action of both suxamethonium 2,3 and mivacurium 2,4,5,6 to be greatly prolonged. We describe a case of prolonged mivacurium paralysis after day surgery. Laboratory investigations showed a genetic tendency toward abnormal cholinesterase levels, but markedly depressed cholinesterase activity was suggestive of additional acquired causes. This patient had a history of liver disease, malnutrition and anticholinesterase use, which we believe were the most significant factors involved.
Prolonged apnoea after muscle relaxants reliant on cholinesterase metabolism is well recognized. A wide range of genetic and physiological states can cause depressed levels or activity of this enzyme. Genetic causes of prolonged paralysis due to mivacurium have been well described. This case highlights the importance of acquired influences on cholinesterase synthesis and activity.
CASE REPORT
A 72 year-old male presented for panendoscopy and tongue biopsy. He was frail looking, 171 cm tall, weighing 66 kg, with an arterial blood pressure of 130/60 mmHg, a pulse rate of 70 min -1 and apyrexial. There was no clinical evidence of cardiovascular or respiratory disease. His abdomen was soft with no hepatomegaly. There were no stigmata of chronic liver disease.
His medical history included stage 3B T-cell lymphoma diagnosed by tongue biopsy ten months previously. He had received six courses of chemotherapy, which included cyclophosphamide, doxo-rubicin, vincristine and prednisone. Over a period of three years he had lost 30 kg. At the time of surgery he was in remission and had received no chemotherapy for six months. Prior to chemotherapy, his cardiac function had been investigated by gated heart pool scan and echocardiography. Left ventricular (LV) function was normal but there was moderate to severe right ventricular (RV) hypokinesis and dilatation. The estimated RV ejection fraction was 30% (normal value 40%).
He had been hospitalized three months previously for acute hepatitis. He had been jaundiced at this time and his plasma alanine transaminase (ALT) and aspartate transaminase (AST) concentrations had peaked at 700 IU/l (normal <35) and 738 IU/l (normal <35) respectively. During the admission, his plasma albumin concentration had fallen to 29 g/l. A deranged coagulation profile prevented liver biopsy (INR 1.8), while viral and autoimmune assays, serum lead and copper levels, computed tomography and ultrasound scans were unhelpful in identifying the aetiology of his jaundice.
He had received general anaesthesia on several recent occasions for ear, nose and throat procedures and for a lumbar laminectomy several years ago. There had been no operation since his episode of hepatitis. Previous anaesthesia had included repeated doses of suxamethonium and mivacurium without apparent prolonged action. He had no known allergies and his regular medications included nasal steroid spray for allergic rhinitis and domperidone for occasional nausea. He was a non-smoker and consumed less than 10 units of alcohol per week.
Preoperative full blood count, electrolytes (including calcium and magnesium), urea and creatinine and liver function tests revealed no abnormalities other than a plasma albumin concentration of 30 g/l. Chest X-ray revealed clear lung fields and a prominent right hilum. A twelve-lead electrocardiogram (ECG) showed left axis deviation and normal sinus rhythm with no evidence of right ventricular or atrial hypertrophy.
Anaesthesia was induced and maintained using a target-controlled infusion of propofol and a remifentanil infusion. Mivacurium 16 mg was administered, a tracheal tube was inserted and the patient's lungs were ventilated with an air-oxygen mixture. Pulse oximetry, non-invasive arterial pressure, 3-lead ECG, and airway CO 2 and O 2 tensions were monitored. All monitored values remained within normal limits during the procedure. Surgery lasted 40 minutes, during which 738 mg of propofol and 1.42 mg of remifentanil were infused. A further 4 mg bolus of mivacurium was administered 10 minutes after induction on a time basis but no nerve stimulator had been used at this stage. On completion of surgery the propofol and remifentanil infusions were stopped. Ten minutes later the patient showed no apparent return of consciousness. Supramaximal train-of-four (TOF) stimulation of the ulnar nerve resulted in no twitch despite changing the stimulator for a new one and repeating the measurement on the contralateral ulnar nerve. The target-controlled infusion of propofol was re-instituted at 1 µg/ml. Ten minutes later, when there was no return of TOF, neostigmine 2.5 mg and glycopyrrolate 0.3 mg were administered. A further 20 minutes later TOF was still absent and a further 1.5 mg of neostigmine was administered. The patient remained ventilatordependent despite an end-tidal CO 2 tension of 50 mmHg. Ulnar nerve stimulation at this stage resulted in four small twitches with significant fade. The patient was transferred to the intensive care unit (ICU).
On arrival in ICU the propofol infusion was continued at 50 mg/h. The TOF count was 4 with significant fade. Tympanic temperature was 35.6°C, arterial blood pressure was 105/60 mmHg and pulse was 75 min -1 . A forced-air warmer was applied. Blood tests, including arterial blood gases were taken approximately 10 minutes after arrival in the ICU. One hour later, the patient was no longer tolerating the tracheal tube, was able to sustain a head-lift for five seconds, had 4/5 grip strength bilaterally and was obeying commands. The propofol infusion was ceased and the patient was extubated. After a total dose of 20 mg mivacurium, paralysis had lasted approximately three hours.
Investigations performed during the period of ventilation in ICU showed a respiratory alkalosis (P a CO 2 23 mmHg) and a plasma albumin concentration of 22 g/l. Liver function tests, plasma electrolytes (including calcium and magnesium), urea and creatinine, full blood count, coagulation profile, plasma troponin concentration and thyroid function tests were normal. Cholinesterase assay revealed cholinesterase activity of 0.8 kU/l (normal range 4.3-10.6), dibucaine number (DN) 83% (normal range 90-95%) and fluoride number (FN) 69% (normal range 72-80%).
DISCUSSION
Mivacurium is metabolized primarily by plasmacholinesterases 1, 4 . Cholinesterase deficiency may be due to a wide range of inherited and acquired causes ( Table 1 ). The DN was depressed and the FN was just below the normal range in this case. The reference ranges for the DN and FN are quite unusual compared with historical figures, but they were confirmed with the chief pathologist (personal communication) as consistent with the specific assay used in this hospital's laboratory. These results are suggestive of a dibucaine-resistant variant of the normal gene 7,3 although a mixed abnormal genotype with the fluoride-resistant gene variant cannot be excluded. These heterozygote variants may not show marked sensitivity to mivacurium 7,3 . This is consistent with previous uneventful administration of mivacurium and suxamethonium. This patient may have had an inherited predisposition toward abnormal metabolism of mivacurium but this was not evident on previous exposure to the drug.
The prolonged paralysis was more likely caused by acquired factors. This hypothesis is supported by the significantly degraded cholinesterase activity. Given the only slightly abnormal dibucaine and fluoride numbers, cholinesterase activity should have been at the lower limits of normal or only slightly abnormal.
Even the mildly depressed levels of plasma cholinesterase during pregnancy affect the metabolism of mivacurium 8, 3 and there have been previous case reports of prolonged mivacurium duration associated with hepatic cirrhosis 9 . This patient's synthetic hepatic function may not have returned to normal after his recent episode of hepatitis although his liver function tests and coagulation profile were normal. This is evidenced by the low albumin level and perhaps accounts for his markedly decreased cholinesterase activity. The cause of his hepatic dysfunction may have been hepatic congestion related to the underlying poor RV function. This may have been exacerbated by his poor nutritional status 3 .
Several factors have been identified as contributing to prolonged neuromuscular block following administration of non-depolarizing muscle relaxants (Table  2 ). Factors potentially contributing to this patient's prolonged block are hypocarbia, low temperature and reversal technique. Although the P a CO 2 was measured at 23 mmHg in the ICU, the end-tidal CO 2 in theatre was 50 mmHg, excluding hypocarbia as a cause for the prolonged paralysis noted in the operating theatre. The patient's initial temperature in ICU was 35.6°C but he was warmed rapidly. We consider it unlikely that the hypothermia contributed significantly to the duration of paralysis.
Due to the short duration of action of mivacurium, no reversal agent is usually required. However, some studies have found that edrophonium, but not neostigmine, assists neuromuscular recovery during profound blockade [10] [11] [12] [13] . These anticholinesterases have different modes of action. Edrophonium's main mechanism of action is to reversibly inhibit acetylcholinesterase; it competes with acetylcholine for the anionic site on the enzyme. Neostigmine transfers a carbamate group to the esteratic site on the enzyme. It has a longer duration of action, as the dissociation of the carbamate/ester complex is slower.
Unlike edrophonium, neostigmine is a potent plasma cholinesterase inhibitor. Neostigmine may cause an early but incomplete reversal of neuromuscular blockade with mivacurium due to action on acetylcholinesterase and cholinesterase. Complete return of neuromuscular function may be very slow 13 . Reversal with neostigmine in this case may have delayed the return of neuromuscular function, especially since it was first administered with no twitches registered on the nerve stimulator.
Given that the investigations for this patient were carried out soon after arrival in the ICU, it is possible that the cholinesterase activity was adversely affected by circulating plasma levels of neostigmine. To delineate the neostigmine contribution, repeat assessment of cholinesterase activity was planned postoperatively but, before this was done, the patient died due to complications of heart failure.
In summary, we present a case of prolonged paralysis due to mivacurium, the cause of which was multifactorial. Although there was a genetic predisposition toward abnormal mivacurium metabolism, acquired factors were probably more significant. There was a marked decrease in cholinesterase activity, perhaps related to impaired synthetic function. We postulate that this was due to hepatic congestion with a possible contribution from malnutrition. Failure to adequately monitor neuromuscular function and the interaction between cholinesterase and neostigmine may have exacerbated the paralysis. This case highlights the importance of considering decreased cholinesterase activity as a cause for prolonged neuromuscular blockade due to mivacurium, the possible utility of monitoring the neuromuscular junction even for short cases, and the potential for neostigmine to adversely affect recovery from mivacurium induced neuromuscular blockade 
